1. Home
  2. BCAB

BCAB

BioAtla Inc.

Logo BioAtla Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-15-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 150.5M IPO Year: 2020
Target Price: $14.50 AVG Volume (30 days): 521.6K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.58 EPS Growth: N/A
52 Week Low/High: $1.24 - $4.07 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: